The Centers for Medicare & Medicaid Services (CMS) has launched a temporary trial offering select GLP-1 weight loss drugs to qualifying Medicare and Medicare Advantage beneficiaries at $50 per month. The program, dubbed Medicare GLP-1 Bridge, runs through 2027 and marks the first time most older adults can get these medications covered strictly for weight loss under federal insurance.
Eligibility hinges on BMI and other health requirements; those already receiving GLP-1s for conditions like diabetes or sleep apnea do not qualify. Of more than 70 million Medicare enrollees, at least 10 million may be eligible, according to CMS. Dr. Mehmet Oz, the agency's administrator, said the trial aims to collect data for potential long-term coverage while providing immediate financial relief.
GLP-1 receptor agonists like Ozempic and Wegovy typically cost hundreds to over a thousand dollars monthly without insurance. The new bridge program dramatically reduces that burden for cash-strapped older Americans, though it does not apply to existing prescriptions for approved medical conditions. Oz emphasized that "the sheer cost of these medications is a huge barrier to access."
This initiative could reshape the weight loss drug market for seniors, opening a path toward broader Medicare coverage. However, the program's temporary nature and strict eligibility criteria limit its immediate impact. Observers will watch whether the data collected prompts permanent policy changes.
Dr. Oz called the program a step toward understanding long-term coverage options, though critics note that without legislative action, patients face uncertainty after 2027.